Volume 2 Supplement 3

Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)

Open Access

TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study

  • Elisabeth Quoix1,
  • Lecia Sequist2,
  • John Nemunaitis3,
  • Thaddeus Beck4,
  • Piotr Jaskiewicz5,
  • Jean-Philippe Oster6,
  • Arnaud Scherpereel7,
  • Erzsébet Juhász8,
  • Zsuzsanna Mark9,
  • Rosa Alvarez10,
  • Saiama Waqar11,
  • Joseph Potz12,
  • Nandagopal Vrindavanam13,
  • Anton Melnyk14,
  • Helen Ross15 and
  • Jean-Marc Limacher16
Journal for ImmunoTherapy of Cancer20142(Suppl 3):O12


Published: 6 November 2014


TG4010 immunotherapy product is a poxvirus (MVA) coding for MUC1 tumor-associated antigen and interleukin-2. A previous study showed that a normal baseline level of Triple Positive Activated Lymphocytes (TrPAL, CD16+CD56+CD69+) might be a predictive biomarker for TG4010 efficacy in advanced NSCLC [1]. TIME is a double-blind Phase IIb/III study comparing the combination of first-line therapy with TG4010 or placebo (NCT01383148).

Patients and methods

Primary endpoint of the Phase IIb part of the study was to compare progression-free survival (PFS, according to RECIST 1.1) between TG4010 and placebo arms using a Bayesian design, in stage IV NSCLC patients whose tumor express MUC1. Secondary objectives were response rate, safety, survival and subgroup analyses according to stratification factors and level of TrPAL at baseline. A dynamic minimization procedure was applied at randomization for histology, prescription of Bevacizumab, type of chemotherapy, performance status and center.


217 patients have been enrolled out of which 170 patients with a normal TrPAL level (pre-determined threshold) and an analysis of PFS was conducted in this cohort after 137 events of progression were recorded. The hazard ratio (HR) for PFS is 0.76 (95%CI: 0.54-1.06). This corresponds to a 97.5% Bayesian probability that the true HR is <1, passing the threshold of 95% needed to consider the endpoint met in patients with normal TrPAL. TG4010 related adverse events were limited to mild or moderate fever and injection site reaction. Analysis in the 75% of patients with the lowest baseline level of TrPAL (three lowest quartiles, n = 152) shows a HR for PFS of 0.72 (95%CI: 0.50-1.03) consistent with the observation made in the previous study. Additional pre-planned analyses by subgroup show that patients with non-squamous tumors had a statistically significant improvement in PFS when treated with TG4010 (n = 145, HR = 0.67; CI: 0.46-0.97; p = 0.016) and especially when belonging to the three lowest quartiles (n = 131, HR = 0.63; 95% CI: 0.42-0.93, p = 0.009). Overall survival data will be presented at the time of the meeting.


These data confirm TG4010 efficacy and safety profile in stage IV NSCLC especially in patients with low level of TrPAL before treatment. They warrant the continuation of the TIME study with its Phase III part.

Authors’ Affiliations

CHRU strasbourg
Massachusetts General Hospital
Mary Crowley Medical Research Center
Highlands Oncology Group
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology - Warsaw
Centre Hospitalier de Colmar
CHRU de Lille Hopital Calmette
Orszagos Koranyi TBC es Pulmonologiai Intezet
Tudogyogyintezet Torokbalint
Hospital Gregorio Marañon
Washington University
Abington Hematology Oncology Associates Inc
Signal Point Clinical Research Center
Texas Oncology, P.A. - Abilene (South)
Mayo Clinic Arizona
Transgene S.A., Illkirch Graffenstaden


  1. Quoix E et al: Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced NSCLC: a controlled phase 2B trial. The Lancet Oncol. 2011, 12: 1125-33. 10.1016/S1470-2045(11)70259-5.View ArticlePubMedGoogle Scholar


© Quoix et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.